ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ERBB3
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ERBB3
16
trial(s) found.
NCT07680790
Advanced
Phase 3
Not yet recruiting
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer (
CA244-0020
)
EGFR inhibitor,third generation
bispecific EGFR/ERBB3 antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07475559
Advanced
Phase 1
Not yet recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Anti-tumor Activity of JSKN016HC in Subjects With Advanced Malignant Solid Tumors (
JSKN016HC-101
)
bispecific ERBB3/TROP2 antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
NCT07111520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (
BNT326-02
)
anti-ERBB3 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Private Hospital
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT07106762
Advanced
Phase 2 / Phase 3
Recruiting
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment (
CA244-0012
)
bispecific EGFR/ERBB3 antibody
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
anti-ERBB3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT07060807
Paed
Phase 3
Recruiting
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04) (
1022-016
)
anti-ERBB3 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06956690
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors (
HMBD-501-101
)
ENV-501
anti-ERBB3 antibody-drug conjugate
cancer therapy
cancer therapy,ERBB3-targeting
immuno-oncology therapy,ERBB3-targeting
+ anti-ERBB3 antibody-drug conjugate
Breast cancer
Melanoma
Non-small cell lung cancer
NSW
2228 - Miranda - Southside Cancer Care Centre (WITHDRAWN)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (WITHDRAWN)
NCT06941272
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (
9999-01C
)
anti-ERBB3 antibody-drug conjugate
Cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06926868
Advanced
Phase 2 / Phase 3
Recruiting
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment (
CA244-0008
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06730386
Advanced
Phase 1
Recruiting
A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors (
AK138D1-101
)
anti-ERBB3 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06618287
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors (
CA244-0001
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06596694
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers (
1022-011
)
anti-ERBB3 antibody-drug conjugate
Gastrointestinal cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06220864
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors (
SNV1521-101
)
PARP1-selective inhibitor
+ anti-ERBB3 antibody-drug conjugate
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05910827
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2065 - St Leonards - GenesisCare North Shore Private Hospital (WITHDRAWN)
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06199908
Advanced
Phase 1
Unknown
First-in-Human, Phase 1 Study of AMT-562 in Patients With Advanced Solid Tumors (
AMT-562-01
)
anti-ERBB3 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Not yet recruiting (2)
Unknown (1)
Recruitment Country and State
NSW (15)
VIC (13)
QLD (10)
WA (8)
SA (4)
NZ (1)
TAS (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (7)
Phase 2 (1)
Phase 2 / Phase 3 (2)
Phase 3 (2)
Trial Type
Advanced (14)
Paed (2)
Cancer Therapy Class
ERBB3
100%
EGFR
31%
PD-1/PD-L1
19%
PD-L1
19%
VEGFA
19%
PD-1
13%
Trop2
6%
SMO
6%
ERBB2
6%
AR
6%
CYP17A1
6%
PARP
6%
PARP1-selective
6%
androgen axis
6%
Facility
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
2109 - North Ryde - Macquarie University Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
3004 - Melbourne, Southbank - Alfred Health (4)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
4120 - Greenslopes - Greenslopes Private Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
5000 - Adelaide - Cancer Research SA (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
4215 - Southport - Tasman Oncology (1)
6009 - Nedlands - One Clinical Research (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2031 - Randwick - Sydney Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2170 - Liverpool - Liverpool Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Breast cancer
Urogenital cancer
Gastrointestinal cancer
Melanoma
Cervical cancer
Gastric cancer
Gastroesophageal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Oesophageal cancer
Upper gastrointestinal cancer
Viral-related cancer
Male genital cancers
Prostate cancer
Urothelial carcinoma
Colorectal adenocarcinoma
Colorectal cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Lower gastrointestinal cancer
Mucosal melanoma
Uveal melanoma
Breast adenocarcinoma
Triple-negative breast cancer
Bladder cancer
Endometrial cancer
Epithelial Ovarian Cancer
Exocrine pancreatic cancer
Head and neck cancer
Head and neck squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Prostate adenocarcinoma
Squamous non-small-cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy